Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
Ryan C. Augustin, Robert D. Leone, Aung Naing, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 2, pp. e004089-e004089
Open Access | Times Cited: 82

Showing 1-25 of 82 citing articles:

Targeting the gut microbiota for cancer therapy
Miriam R. Fernandes, Poonam Aggarwal, Raquel Costa, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 12, pp. 703-722
Closed Access | Times Cited: 156
CD39/CD73/A2AR pathway and cancer immunotherapy
Chenglai Xia, Shuanghong Yin, Kenneth K.W. To, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 154
Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
Feyza Gül Özbay Kurt, Samantha Lasser, Ihor Arkhypov, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 13
Open Access | Times Cited: 62
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Lei Peng, Giacomo Sferruzza, Luojia Yang, et al.
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 10, pp. 1089-1108
Open Access | Times Cited: 43
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
Alessandra Cesano, Ryan C. Augustin, Luigi Barrea, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e008876-e008876
Open Access | Times Cited: 2
Discovery of the First Efficacious Adenosine 2A Receptor Negative Allosteric Modulators for High Adenosine Cancer Immunotherapies
Margot Boujut, Margaux Héritier, Aurélie Gouiller, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 2
Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death
Xuhui Bao, Liyi Xie
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 44
The Clinical Significance of CD73 in Cancer
Niklas Bach, Riekje Winzer, Eva Tolosa, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11759-11759
Open Access | Times Cited: 31
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
Abdul Rafeh Naqash, Justin McCallen, Emma Mi, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 10, pp. e007310-e007310
Open Access | Times Cited: 28
The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy
John Stagg, Encouse B. Golden, Erik Wennerberg, et al.
Science Immunology (2023) Vol. 8, Iss. 85
Open Access | Times Cited: 24
Evolution of myeloid-mediated immunotherapy resistance in prostate cancer
Aram Lyu, Zenghua Fan, Matthew Clark, et al.
Nature (2024)
Open Access | Times Cited: 14
The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma
Yifan Zhang, Shengli Zhang, Hongbin Sun, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 1
CD39 – A bright target for cancer immunotherapy
Shuwei Guo, Fengfeng Han, Wei Zhu
Biomedicine & Pharmacotherapy (2022) Vol. 151, pp. 113066-113066
Open Access | Times Cited: 35
Role of adenosine A2a receptor in cancers and autoimmune diseases
Hongling Ye, Jun-Qi Zhao, Xuejing Xu, et al.
Immunity Inflammation and Disease (2023) Vol. 11, Iss. 4
Open Access | Times Cited: 23
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
Kamlesh Bisht, Taro Fukao, Marielle Chiron, et al.
Cancer Medicine (2023) Vol. 12, Iss. 20, pp. 20332-20352
Open Access | Times Cited: 23
Drugs targeting adenosine signaling pathways: A current view
Barbara Kutryb-Zając, Ada Kawecka, Khrystyna Nasadiuk, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115184-115184
Open Access | Times Cited: 19
From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review
Moksada Regmi, Yingjie Wang, Weihai Liu, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review
Marco Merlano, Nerina Denaro, Danilo Galizia, et al.
Biomedicines (2022) Vol. 10, Iss. 8, pp. 1822-1822
Open Access | Times Cited: 27
Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis
Zhaowei Gao, Lan Yang, Chong Liu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 23
The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers
Ruiyang Ren, Chenyi Xiong, R.C-S. Ma, et al.
MedComm (2023) Vol. 4, Iss. 4
Open Access | Times Cited: 16
Tumor derived exosomal ENTPD2 impair CD8+ T cell function in colon cancer through ATP-adenosine metabolism reprogramming
Mengchen Shi, Linsen Ye, Lu Zhao, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
CD73 contributes to the pathogenesis of fusion-negative rhabdomyosarcoma through the purinergic signaling pathway
Karla Cano Hernandez, Akansha M. Shah, Víctor López, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 4
Open Access | Times Cited: 5
HPV-Positive and -Negative Cervical Cancers Are Immunologically Distinct
Andris M. Evans, Mikhail Salnikov, Steven F. Gameiro, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 16, pp. 4825-4825
Open Access | Times Cited: 21
Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status
Lisa Schlicher, Luke G. Green, Andrea Romagnani, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
Chenyu Zhu, Shuyin Ze, Ronghui Zhou, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 4734-4754
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top